Purple Biotech (PPBT) Other Non-Current Liabilities (2019 - 2026)

Purple Biotech (PPBT) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 361.56% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 361.56% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 253.87% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.9 million, down from $4.1 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for PPBT reached as high as $4.1 million in Q3 2025 and fell as low as $267000.0 in Q2 2025.
• Historically, Other Non-Current Liabilities has averaged $1.9 million across 4 years, with a median of $1.7 million in 2024.
• Across the five-year window, Other Non-Current Liabilities sank 79.91% in 2025 and soared 361.56% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $2.5 million in 2023, then sank by 54.37% to $1.1 million in 2024, then jumped by 253.87% to $4.1 million in 2025, then plunged by 53.34% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $1.9 million in Q1 2026, $4.1 million in Q4 2025, and $4.1 million in Q3 2025.